Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Progenics Pharmaceuticals Inc (NASDAQ:PGNX)

5.57
Delayed Data
As of Aug 18
 -0.10 / -1.76%
Today’s Change
4.60
Today|||52-Week Range
11.72
-35.53%
Year-to-Date

Five Year Financial Summary

Total Revenue

Cash & Short Term Investments

Cash From Operations

All Currency in US Dollars4 Quarter
Trend
Quarter 3
2016
Quarter 4
2016
Quarter 1
2017
Quarter 2
2017
Revenue and IncomeNet Revenues53.9M4.7M2.3M2.8M
 
 
 
 
 
Depreciation And Amortization362.0K218.0K256.0K288.0K
 
 
 
 
 
 
Operating ExpensesGross Income----------
General Expenses16.7M15.1M15.4M17.3M
 
 
 
 
 
Research And Development9.8M10.6M10.0M11.3M
 
 
 
 
 
Total Operating Expenses17.0M15.3M15.7M17.6M
 
 
 
 
 
 
Non-Operating ExpensesOperating Income36.8M-10.7M-13.4M-14.9M
 
 
 
 
 
Extraordinary Credit0.006.0M0.000.00
 
 
Extraordinary Charge-600.0K0.00-1.9M-700.0K
 
 
 
 
Interest Expense On Debt0.00800.0K1.3M1.2M
 
 
 
 
Other Expenses0.00-34.0K0.000.00
 
 
 
Income Taxes, Minority Interest and Extra ItemsPre-Tax Income36.3M-5.4M-16.4M-16.6M
 
 
 
 
 
Income Taxes0.00-1.8M0.000.00
 
 
Minority Interest-21.0K-15.0K0.000.00
 
 
 
Net Income36.3M-7.2M-16.4M-16.6M
 
 
 
 
 
 
Shares To Calculate EPSShares To Calculate EPS70.0M70.1M70.2M70.2M
 
 
 
 
 
Shares To Calculate EPS Diluted70.3M70.1M70.2M70.2M
 
 
 
 
 
 
Earnings Per ShareEPS$0.52-$0.10-$0.23-$0.24
 
 
 
 
 
EPS Diluted$0.52-$0.10-$0.23-$0.24